XML 54 R32.htm IDEA: XBRL DOCUMENT v3.4.0.3

Equity Instruments (Tables)

6 Months Ended

12 Months Ended

Dec. 31, 2015

Jun. 30, 2015

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

Aytu has computed the fair value of all options granted during the six months ended December 31, 2015 using the following assumptions:

Expected volatility			75.00%
Risk free interest rate			1.08% – 2.08%
Expected term (years)			3.0 – 7.0
Dividend yield			0%

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

Stock option activity is as follows:

		Number of Options				Weighted Average Exercise Price				Weighted Average Remaining Contractual Life in Years
Outstanding June 30, 2015			—			$	—
Granted			3,695,000			$	1.55
Exercised			—			$	—
Forfeited/Cancelled			—			$	—
Outstanding December 31, 2015			3,695,000			$	1.55				9.80
Exercisable at December 31, 2015			1,120,000			$	1.51				9.87
Available for grant at December 31, 2015			6,305,000

Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]

The following table summarizes stock-based compensation expense for the three and six months ended December 31, 2015 and for the stock-based compensation expense related to the Luoxis and Vyrix options for the three and six months ended December 31, 2014:

		Three Months Ended December 31,								Six Months Ended December 31,
		2015				2014				2015				2014
Research and development expenses
Stock options		$	20,000			$	117,000			$	25,000			$	207,000
Selling, general and administrative expenses
Stock options		$	163,000			$	159,000				226,000				271,000
		$	183,000			$	276,000			$	251,000			$	478,000
Unrecognized expense at December 31, 2015		$	1,890,000
Weighted average remaining years to vest			3.16

The following table summarizes stock-based compensation expense for the years ended June 30 2015 and 2014:

		Years Ended June 30,
		2015				2014
Research and development expenses
Stock options
Luoxis		$	427,000			$	206,000
Vyrix			92,000				38,000
General and administrative expenses
Stock options
Luoxis			316,000				152,000
Vyrix			183,000				104,000
		$	1,018,000			$	500,000
Unrecognized expense at June 30, 2015
Luoxis		$	—
Vyrix		$	—
Weighted average remaining years to vest
Luoxis			—
Vyrix			—

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

A summary of these warrants is as follows:

		Number of Warrants				Weighted Average Exercise Price				Weighted Average Remaining Contractual Life in Years
Outstanding June 30, 2015			102,613			$	4.53				2.92
Outstanding December 31, 2015 (unaudited)			102,613			$	4.53				2.41

Aytu issued warrants in conjunction with its 2013 private placement. A summary of all warrants is as follows:

		Number of Warrants				Weighted Average Exercise Price				Weighted Average Remaining Contractual Life
Outstanding June 30, 2013			102,613			$	4.53				4.41
Outstanding June 30, 2014			102,613			$	4.53				3.92
Outstanding June 30, 2015			102,613			$	4.53				2.92

Luoxis Diagnostics [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

The assumptions are as follows:

		Years Ended June 30,
		2015				2014
Expected volatility			79% – 108%				79% – 82%
Risk free interest rate			1.62% – 2.09%				0.75% – 1.53%
Expected term (years)			5.5 – 7.0				5.0 – 6.5
Dividend yield			0%				0%

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

Stock option activity is as follows:

		Number of Options				Weighted Average Exercise Price				Weighted Average Remaining Contractual Life				Aggregate Intrinsic Value
Outstanding June 30, 2013			396,994			$	4.53				9.96			$	1,272,000
Granted			33,083			$	4.53
Exercised			—			$	—
Forfeited/Cancelled			—			$	—
Outstanding June 30, 2014			430,077			$	4.53				9.01			$	1,374,000
Granted			195,189			$	7.25
Exercised			—			$	—
Forfeited/Cancelled			(625,266	)		$	5.40
Outstanding June 30, 2015			—			$	—
Exercisable at June 30, 2015			—			$	—
Available for grant at June 30, 2015			—

Vyrix Pharmaceuticals Inc [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

The assumptions are as follows:

		Year Ended June 30, 2014
Expected volatility			63% – 76%
Risk free interest rate			0.90% – 2.02%
Expected term (years)			5.0 – 6.5
Dividend yield			0%

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

Stock option activity is as follows:

		Number of Options				Weighted Average Exercise Price				Weighted Average Remaining Contractual Life				Aggregate Intrinsic Value
Outstanding June 30, 2013			—			$	—				—			$	—
Granted			117,053			$	5.68
Exercised			—			$	—
Forfeited/Cancelled			—			$	—
Outstanding June 30, 2014			117,053			$	5.68				9.54			$	417,000
Granted			—			$	—
Exercised			—			$	—
Forfeited/Cancelled			(117,053	)		$	5.68
Outstanding June 30, 2015			—			$	—
Exercisable at June 30, 2015			—			$	—
Available for grant at June 30, 2015			—

X

- Definition

Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name:	us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name:	us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name:	us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51659978&loc=d3e25284-112666

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 28
-Article 5

+ Details

Name:	us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	dei_LegalEntityAxis=aytu_LuoxisDiagnosticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	dei_LegalEntityAxis=aytu_VyrixPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: